eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).
EFTR
0.363343 as of 3/27/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 8/24/2017 | Series C | $197.73MM | $XXX.XX | $XXX.XX |
| 12/22/2015 | Series B | $141.22MM | $XXX.XX | $XXX.XX |
| 5/20/2013 | Series A | $67.04MM | $XXX.XX | $XXX.XX |
